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Abstract
Background: Ectopic pregnancy is a potentially life-threatening condition occurring in 1-2 % of all pregnancies. The
most common ectopic implantation site is the fallopian tube, though 10 % of ectopic pregnancies implant in the
cervix, ovary, myometrium, interstitial portion of the fallopian tube, abdominal cavity or within a cesarean section scar.
Findings: Diagnosis involves a combination of clinical symptoms, serology, and ultrasound. Medical management is a
safe and effective option in most clinically stable patients. Patients who have failed medical management, are
ineligible, or present with ruptured ectopic pregnancy or heterotopic pregnancy are most often managed with
excision by laparoscopy or, less commonly, laparotomy. Management of nontubal ectopic pregnancies may involve
medical or surgical treatment, or a combination, as dictated by ectopic pregnancy location and the patient's clinical
stability. Following tubal ectopic pregnancy, the rate of subsequent intrauterine pregnancy is high and independent
of treatment modality.
Conclusion: This review describes the incidence, risk factors, diagnosis, and management of tubal and non-tubal
ectopic and heterotopic pregnancies, and reviews the existing data regarding recurrence and future fertility.
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Findings
An ectopic pregnancy (EP) refers to the implantation of
an embryo outside of the uterus. Due to advances in la-
boratory testing, transvaginal ultrasound, chemotherapy
and laparoscopy, the evaluation, diagnosis and manage-
ment of EP has rapidly evolved. In parallel, maternal
mortality has declined, from 3.5 of 10,000 pregnancies in
1970 to 2.6 of 10,000 in 1992 [1].
The most common EP location is in the fallopian tube,
predominantly the ampullary region of the fallopian tube.
Implantation outside the fallopian tube—in the cervix,
ovary, myometrium, abdominal cavity, interstitial (i.e.,
intramuscular/proximal) portion of the fallopian tube or
coincidentally with an intrauterine pregnancy—occurs in
less than 10 % of EPs. Heterotopic pregnancy (HP) refers
to the coexistence of an intrauterine pregnancy with an EP
in any of these locations. ‘Cornual’ pregnancies are those
implanted in a horn of an anomalous uterus (i.e., unicornu-
ate, bicornuate, didelphys or septate uteri); these do not
uniformly require intervention and will not be included in
this review [2–4].
This review will describe the incidence, risk factors,
diagnosis and management of women with tubal and
nontubal EPs, as well as review the existing literature
regarding their future fertility.
Review
Incidence
The overall rate of EP is 1–2 % in the general population,
and 2–5 % among patients who have utilized assisted
reproductive technology (ART) [5, 6]. Although the over-
all mortality has decreased over time, ruptured EPs still
account for up to 6 % of all maternal deaths; a review of
mortality in ART-associated EPs similarly reported a mor-
tality rate of 31.9 deaths per 100,000 pregnancies [5, 7].
Nontubal EPs are pregnancies that implant at sites other
than the fallopian tube. These pregnancies account for less
than 10 % of all EPs, though their overall incidence has
been increasing in recent years [5]. Furthermore, nontubal
EPs contribute disproportionately to maternal morbidity
and mortality in comparison to tubal EPs. Cervical EPs are
estimated to occur in 1:2000 to 1:18,000 pregnancies [8].
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The estimated incidence of cesarean scar EPs is 1:1800 to
1:2216 pregnancies, or 6 % of all EPs in women with at
least one cesarean delivery [9, 10]. Interstitial EPs account
for 4 % of EPs, though the associated morbidity is much
higher, with mortality rates of 2.5 % or 7 times the mortal-
ity rate associated with other EP locations, largely due to
hemorrhage [11, 12]. Pregnancies embedded within the
myometrium (intramural EPs) account for an estimated
1 % of EPs [13]. Abdominal pregnancies account for 1.3 %
of EPs [14]. These have been classified as primary or sec-
ondary; secondary abdominal EPs are theorized to result
from extrusion from the fallopian tube and subsequent
intraabdominal reimplantation [15]. Most common im-
plantation sites are in the pouches posterior and anterior
to the uterus and on the serosa of the uterus and adnexa;
retroperitoneal, omental, bowel, hepatic and splenic im-
plantations have also been reported [16].
Estimates of the incidence of heterotopic pregnancy
(HP) vary by article and decade; the risk has been reported
from 1:4000 to 1:30,000 women in the general population
[5, 17]. The risk of HP following in vitro fertilization (IVF)
has been estimated as high as 1:100 women [5, 17, 18].
HPs can include an EP in any of the previously described
locations; a triplet HP that included tubal and cervical EPs
has even been described [19]. The majority are tubal HPs;
in a review of 80 cases of HP in the literature, 66 (72.5 %)
were in the ampullary or interstitial portion of the fallo-
pian tube, while 7 were cervical and 3 were implanted in
the cesarean scar [17].
Etiology of tubal ectopic pregnancy
The fallopian tube is a carefully controlled environment to
facilitate oocyte transport, fertilization, and migration of
the early embryo to the uterus for implantation [20] Most
data suggest tubal EP stems from both abnormal embryo
transport and an alteration in the tubal environment,
which enables abnormal implantation to occur [21].
The transport of an oocyte and embryo through the tube
relies on both smooth muscle contraction and ciliary beat-
ing, which are affected by several local factors—toxic, infec-
tious, immunologic and hormonal. Smoking and infection
have been shown to decrease cilia density, while ciliary beat
frequency has been shown to be responsive to the changing
hormonal milieu of the menstrual cycle [22–24]. Samples
of fallopian tube epithelium incubated in estradiol (E2) and
nitric oxide (NO) have been found to demonstrate in-
creased ciliary motility, which may cause aberrant tubal
transport [25, 26]. NO also affects smooth muscle contract-
ility in the fallopian tube; expression of NO has been found
to vary during the menstrual cycle, with possible implica-
tions for normal and ectopic implantations [27]. Finally,
E2-mediated effects via estrogen receptors on gene regula-
tion and expression—including pathways implicated in im-
plantation and apoptosis—may be involved in aberrant
tubal function and ectopic pregnancy, though more re-
search is needed to clarify these pathways [28–30].
Inflammation in the fallopian tubes is also implicated in
the establishment of EP, by inducing tubal dysfunction or
damage that may lead to retention of an oocyte or
embryo, and by promoting embryo implantation in the
fallopian tube via inflammatory cytokines [31]. Following
tubal damage by smoking or infection, upregulation of
pro-inflammatory cytokines has been noted, promoting
embryo receptivity, invasion and angiogenesis in the tube.
For instance, interleukin 1 (IL-1), produced by tubal
epithelial cells following Chlamydia trachomatis infection,
is a vital signal for embryo implantation in the endomet-
rium; IL-1 also recruits neutrophils downstream, leading
to further tubal damage [32]. Macrophages and intrae-
pithelial lymphocytes are also increased in women with
EP, potentially affecting tubal function and predisposing to
tubal EP [33–35].
Clinical risk factors
Up to 50 % of women diagnosed with EPs have no iden-
tifiable risk factors; however, a number of risk factors
have been associated with EP [5]. These include age,
smoking, history of EP, tubal surgery or tubal damage,
prior pelvic infection, DES exposure, IUD use and preg-
nancy conceived by assisted reproduction.
Age has been shown to be a risk factor for EP, with the
highest incidence over the age of 35 in both spontaneous
pregnancies and those conceived after assisted reproduct-
ive technologies [7, 36]. The explanation for this observa-
tion is unknown, however age is theorized to affect tubal
function, including delay of oocyte transport [36, 37].
Prior EP is a strong risk factor for recurrent EP, with a
recurrence rate of 5–25 %, or up to 10 times the risk in
the general population [38–40]. Prior treatment for EP,
whether medical or surgical, may result in pathologic
changes in tubal motility, ciliary function and uterine
contractions [41]. (For fertility outcomes after prior EP,
please see “Recurrence and future fertility”).
Smoking is thought to increase the risk of EP by caus-
ing tubal dysfunction, including deciliation [22]. To-
bacco may cause dysregulation of the paracrine signals
needed for coordinated embryo transport and develop-
ment [21]. In a retrospective review of 481 IVF cycles,
the likelihood of a tubal EP was three times higher
among smokers [41]. A dose-dependent relationship be-
tween smoking and EP has also been confirmed in spon-
taneous pregnancies [36].
A history of pelvic infection or pelvic inflammatory
disease is associated with increased risk for subsequent
EP. Chlamydia trachomatis in particular has been impli-
cated as a risk factor for EP, with the risk increasing with
each successive infection; ascending infection and result-
ant salpingitis is thought to lead to tubal dysfunction
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and aberrant implantation [5, 21, 42, 43]. Other infec-
tions potentially associated with pelvic inflammatory
disease and tubal damage include Neisseria gonorrhoeae,
Mycoplasma and schistosomiasis [44, 45].
Prior tubal surgeries, including but not limited to tubal
reanastamosis, salpingostomy, tuboplasty and lysis of ad-
hesions, are risk factors for EP. Similarly, any causes of
pelvic adhesions, including endometriosis, appendicitis,
or other pelvic surgeries, may distort the anatomy of the
fallopian tube [46, 47]. The risk of EP after tubal reanas-
tamosis, specifically, is estimated at 2–13 %, and is simi-
lar between abdominal and robotic approaches [6, 48].
After surgical sterilization, the failure rate across all
sterilization methods is estimated at 18.5 per 1000,
approximately one-third of which are EPs [49]. Women
sterilized before 30 years of age are twice as likely to
have subsequent EPs as those sterilized after age
30 years. Rates of EP vary by sterilization technique:
After bipolar coagulation, 65 % of pregnancies are EP,
while after unipolar or clip sterilization, approximately
15 % of pregnancies are EP [50]. The proportion of EP
has been shown to be three times higher between 4 and
10 years after sterilization, as compared to the first
3 years [49].
Current IUD use dose not predispose to EP, though a
higher proportion of pregnancies conceived with an IUD
in place are ectopic as compared to the general popula-
tion [43, 51]. Among pregnancies conceived with IUDs
in place, half are ectopic with a levonogestrel device in
place, compared to 1:16 with a copper IUD in place [52].
Overall, any contraceptive use decreases the risk of both
intrauterine and ectopic pregnancy.
Assisted reproductive technologies constitute a risk fac-
tor for EP, as 2–5 % of pregnancies from assisted repro-
ductive technologies are ectopic [7]. The three main
factors contributing to this increased risk are the specific
type of procedure, the reproductive health characteristics
of the woman, and the estimated embryo implantation po-
tential [21, 53]. A history of infertility, even in the absence
of known tubal disease, is associated with EP, with the EP
risk increasing with a longer duration of infertility [18, 43].
Tubal factor infertility specifically is associated with a two-
fold risk of EP following IVF [52, 54, 55].
Several IVF cycle parameters may be associated with
an increased risk of EP. Patients undergoing cycles trig-
gered with gonadotropin releasing hormone (GnRH)
agonists instead of recombinant hCG may be at higher
risk of EP; in a review of 466 IVF cycles, GnRH agonist
triggers were associated with a significantly higher EP
rate (5.3 % versus 1.4 % following hCG triggers). This
finding is theorized to be due to poor endometrial recep-
tivity following GnRH agonist administration [56].
The number of embryos transferred may be correlated
to the EP risk; in a review of 9480 ectopic pregnancies
following IVF, the rate of EP following fresh cycles rose
significantly from 1.7 % following single embryo transfer
to 2.5 % following the transfer of 4 embryos [7]. Depth of
transfer may also have an effect; a randomized prospective
study of deep versus mid-fundal transfer reported an EP
rate of 1.5 versus 0.4 % [57]. Day of embryo transfer has
inconsistently been associated with risk of EP in prior
studies. A series of 13,654 fresh cycles reported an EP rate
of 2.1 % following day 3 embryo transfers, as compared to
a rate of 1.6 % following day 5 embryo transfers, which did
not reach statistical significance [58]. Conversely, a review
of 1994 fresh transfers reported a significant difference in
ectopic pregnancy rates between day 3 and day 5 transfers,
at 2.4 and 1.7 %, respectively [59].
The transfer of fresh embryos is associated with a higher
EP risk as compared to the transfer of thawed embryos;
following 15,042 fresh cycles, the EP rate was 1.97 %,
which was significantly higher than the 1.01 % EP rate
following 12,752 cryopreservation cycles [55]. It is theo-
rized that the controlled ovarian hyperstimulation and
hyperestrogenic environment preceding a fresh embryo
transfer negatively effects endometrial receptivity [60].
Risk factors for nontubal EP
Overall, the risk factors for ovarian EPs, interstitial EPs,
and tubal HPs are similar to those for tubal pregnancy.
These include a history of a prior EP, pelvic infections and
use of in vitro fertilization [61]. The transfer of four or
more embryos during IVF is an additional risk factor for
HP [18, 62]. IUD use may be a risk factor for nontubal EP,
particularly for ovarian EP [63]. An additional risk factor
for interstitial implantation includes prior ipsilateral sal-
pingectomy, with interstitial ectopic pregnancies occur-
ring up to 13 years after salpingectomy [4]. Risk factors
for other specific types of nontubal EPs are outlined in the
following subsections.
Intramural EP
Risk factors for these rare EPs are theorized to include
myometrial injury following uterine curettage, and prior
myomectomy or cesarean section [13]. Assisted repro-
ductive technologies have been used in approximately
20 % of case reports, and another 19 % of patients car-
ried a diagnosis of adenomyosis.
Cesarean section EP
Risk for cesarean scar implantation is not clearly corre-
lated to the number of prior cesarean sections [64]. Risk
for cesarean section scar implantation has not been cor-
related to single versus double layer closure of the hys-
terotomy at the time of cesarean section. Cesarean scar
implantation may be more common following cesarean
sections for elective indications, which is theorized to be
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due to impaired healing of an unlabored lower uterine
segment [65].
Cervical EP
A history of dilation and curettage (D&C) in a previous
pregnancy has been associated with subsequent cervical
EP; this risk factor is present in nearly 70 % of cases
[66, 67] In-vitro fertilization has been proposed as a
risk factor, but often coincides with D&C and other
possible risk factors, so is difficult to isolate as an inde-
pendent contributor to risk [68].
Abdominal pregnancy
Risk factors for abdominal pregnancy are similar to those
for tubal EPs, including pelvic inflammatory disease, use
of assisted reproductive technologies and endometriosis
[69]. Most abdominal pregnancies have been published in
case reports; one details the occurrence of a twin preg-
nancy implanted in the broad ligament after IVF. Uterine
perforation was suggested as a possible cause as the em-
bryo transfer was performed using a stylet, which is more
rigid than standard transfer catheters [70].
Diagnosis
Serum beta-human chorionic gonadotropin (β-hCG)
The diagnosis of EP often begins with the preliminary
diagnosis of pregnancy of unknown location (PUL). PUL
is defined as a positive serum beta-human chorionic
gonadotropin (β-hCG) in the absence of ultrasound find-
ings indicative of intrauterine or extrauterine pregnancy.
Approximately 30 % of patients with PUL will develop
an ongoing intrauterine pregnancy (IUP), while the
majority (50–70 %) will be diagnosed with failing preg-
nancies, either miscarriages or EPs [71].
In the stable patient, measurement of β-hCG is crucial
to clarify pregnancy location and prognosis. Produced pri-
marily by the syncytiotrophoblast in the placenta, β-hCG
is detectable in the blood by the second week of preg-
nancy until a peak at 10–12 weeks [72]. A single measure
of β-hCG is insufficient to clarify pregnancy prognosis,
and serial β-hCG levels are commonly used to monitor
early pregnancies. The most recent recommendations for
β-hCG trends in early pregnancy, derived from a retro-
spective review of 1005 patients with PUL, suggest the
minimum β-hCG rise of an IUP is 35 % in 2 days [73]. A
β-hCG rise less than 35 % in 2 days has a positive predict-
ive value of 96.2 %, a negative predictive value of 69.7 %,
and an overall accuracy of 80.2 % in predicting EP.
Conversely, in this study, in patients eventually diag-
nosed with miscarriages, the minimum expected β-
hCG decline in 2 days is 36–47 % (depending on the
starting β-hCG level). Β-hCG cut-offs, however, are not
ironclad; using these cut-offs, 16.8 % of EPs and 7.7 %
of IUPs would be misclassified solely using serial β-
hCG levels. Obtaining a third β-hCG and early ultra-
sound decreased the misclassification of IUP to 2.7 % [73].
The expected rates of β-hCG rise and decline are the same
for multiple pregnancies, following assisted reproduction,
and in obese patients [74]. The absolute β-hCG values,
however, may be higher in multiple pregnancies or lower
in patients with elevated body mass index.
Serum progesterone
Serum progesterone has been explored as a possible serum
marker for nonviable pregnancies, including EPs, as pro-
gesterone levels have been shown to be lower in ectopic
and failing pregnancies than IUPs [75]. Several studies sug-
gest a progesterone cut-off of 10 nanograms per milliliter
(ng/mL) for the most accurate identification spontaneous
EPs. In a meta-analysis including 4689 patients under
14 weeks gestational age with pain and/or bleeding, a
serum progesterone level of less than 10 ng/mL predicted
a non-viable pregnancy with a sensitivity of 66.5 % and spe-
cificity of 96.3 % [76]. The optimal cut-off may be higher in
patients who received fertility treatments, as these patients
often have multiple corpora lutea secreting progesterone
and often receive exogenous progesterone. A cut-off of
30 ng/mL, 28–49 days after the last menstrual period, may
be more appropriate in patients who received clomiphene
citrate, while an optimal cut-off has yet to be identified in
patients after IVF and is likely highly dependent on the
number of days since embryo transfer [77, 78].
Serum progesterone levels, however, have been shown
to misclassify more normal pregnancies than serial β-hCG
measurements [79]. Serum progesterone also cannot fur-
ther distinguish between miscarriages and EPs. While pro-
gesterone may highlight patients at greater risk for EP, it is
insufficient in itself to discriminate between IUPs, miscar-
riages and EPs [80].
Other serum markers
Several studies have explored alternative serum markers
of EP, focusing on proteins associated with placental,
endometrial and/or corpus luteal functions, angiogen-
esis and inflammation [75]. These potential proteins
include, but are not limited to: Inhibin A, which is
produced by the corpus luteum; activin A, pregnancy-
associated plasma protein-A (PAPP-A) and A Disinte-
grin and Metalloprotease-12 (ADAM-12) which are
generated by the placenta; and vascular endothelial growth
factor (VEGF), which, produced by a variety of cell types,
is crucial for angiogenesis and may be upregulated in EP
[75]. Various messenger and micro-RNA—regulators of
downstream gene expression—may also be differentially
expressed by an EP [81, 82].
Studies have also attempted to combine multiple mea-
sures; one such study incorporated VEGF, PAPP-A, and
progesterone, and reported sensitivity of 97.7 % and
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specificity of 92.4 % in diagnosing EP, though this model
has not been validated in further studies [83]. For many
of these markers, studies are inconclusive, and for all
markers, more research is needed before any of these
supplants β-hCG as the primary serologic method of
differentiating intra- and extrauterine pregnancies [81].
Imaging
Discriminatory zone
Visualization of a gestational sac by transvaginal ultra-
sound (TVUS), confirming an intrauterine pregnancy
(IUP), is expected at serum β-hCG levels above the “dis-
criminatory zone.” The discriminatory zone was initially
proposed as 6500 milli-international units (mIU)/mL in
1981, using transabdominal ultrasound [84]. With ad-
vances in ultrasound imaging, particularly with the use
of transvaginal sonography, the discriminatory zone has
been lowered to 1000 to 2000 mIU/mL [85].
Studies report that normal IUPs may still develop in
patients with PULs and serum β-hCGs above the dis-
criminatory zone. In a review of patients with PUL,
nine women with β-hCGs above 2000 mIU/mL at the
time of their TVUS developed intrauterine pregnancies;
the highest β-hCG in this group was 4336 mIU/mL
[86]. In patients with multiple pregnancies, the serum
β-hCG at which an intrauterine gestational sac is seen can
be higher than the discriminatory zone identified for
singleton IUPs. One review reported a serum β-hCG of
9083 mIU/mL without definitive ultrasound findings in a
patient later diagnosed with a triplet pregnancy [87].
Other factors such as obesity or uterine fibroids may also
be associated with nonvisualization of an intrauterine
gestational sac above the β-hCG discriminatory zone.
Serum β-hCG in the absence of definitive ultrasound
findings should not be the sole factor in diagnosing
pregnancy location or viability or dictating management,
and that gestational age must be taken into account. A
positive pregnancy test at any level in the absence of an
intrauterine pregnancy should be approached as an EP
until proven otherwise.
Accessory ultrasound findings
In the absence of definitive visualization of an EP, additional
markers on ultrasound can increase a clinician’s suspicion
for EP, and may be useful in conjunction with other clinical
data. These include a thin endometrial stripe thickness and
the presence of intraabdominal free fluid.
In a review of 591 patients with vaginal bleeding and
PUL, IUPs had a significantly higher mean endometrial
stripe thickness than miscarriages or EPs (17 mm versus
12 mm, respectively); no intrauterine pregnancies oc-
curred in patients with endometrial stripes below 8 mm in
thickness [88]. However, studies have not consistently
shown a significant difference in endometrial stripe thick-
ness between miscarriages and EPs [89]. Endometrial
stripe thickness may indicate patients at higher risk for
abnormal pregnancies but cannot reliably be used in isola-
tion to diagnose EP [90].
A small amount of anechoic free fluid in the posterior
cul de sac is normal in both intra- and extrauterine preg-
nancies [91]. Larger amounts of complex free fluid, par-
ticularly in Morrison’s pouch by the liver, may indicate
rupture of an EP, and correlates well to hemoperitoneum
observed intraoperatively [91, 92]. Hemoperitoneum can
be assessed in the emergency setting using a Focused
Assessment with Sonography for Trauma (FAST) scan,
which is a bedside ultrasound assessing for free fluid in the
perihepatic, perisplenic and pelvic space; the full trauma
assessment, not applicable to patients with suspected EP,
also includes the pericardial space [93]. The determination
of extent of hemoperitoneum and need for intervention
depends on clinician assessment and the patient's
hemodynamic stability. Of note, if an ultrasound shows an
IUP, the risk of EP is much reduced, though not zero.
Though rare, the patient may still be at risk of heterotopic
pregnancy, particularly following IVF [94].
Ultrasound diagnosis of tubal EP
In women presenting with bleeding or pain, pregnancy
location is often not definitively visualized on the initial
ultrasound at presentation; however, diagnosis of EP by
ultrasound is possible when following careful guidelines.
Identification of a gestational sac and fetal pole, with or
without cardiac activity, or a hyperechoic ring—called
the ‘bagel’ or ‘tubal’ sign (Fig. 1)—with circumferential
Doppler flow (Fig. 2) is highly suggestive of an ectopic
pregnancy [95, 96]. If a suspicious mass moves separ-
ately from the ovary—called the ‘blob’ sign - the positive
predictive value is above 90 % in a symptomatic woman
with a positive serum b-hCG and no IUP on transvaginal
ultrasound [97, 98].
Ultrasound findings specific to nontubal EPs
Ectopic pregnancies occurring in less common anatomic
areas can also be identified by ultrasound according to
specific criteria. Diagnostic criteria of each type of nontu-
bal ectopic pregnancy are discussed below. All of these
diagnostic criteria assume the absence of a visualized IUP.
Ultrasound criteria for diagnosis of an interstitial ec-
topic pregnancy include a gestational sac at least 1 cm
lateral to the edge of the uterine cavity, with a thin
(5 mm or less) layer of overlying myometrium surround-
ing it (Figs. 3 and 4) [99, 100]. An ‘interstitial line’ may
also be seen (Fig. 5) [101].
A cervical EP is identified on ultrasound by a distended
cervical canal containing a gestational sac with peripheral
Doppler flow (Fig. 6), below a closed internal cervical os
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[102, 103]. The ‘sliding organ’ sign, or movement when
pressure is applied with the transvaginal probe, is associ-
ated with spontaneous abortions in progress and should
be absent in a cervical ectopic pregnancy.
Diagnostic criteria for a cesarean scar EP by ultrasound
include visualization of the gestational sac at the site of the
prior hysterotomy (Fig. 7), outside the endometrial cavity
[104]. The myometrium should be very thin (1–3 mm) or
absent between the gestational sac and the bladder (Fig. 8).
A negative ‘sliding organ’ and the presence of peripheral
Doppler flow are expected [9].
On ultrasound or MRI, intramural EPs should be com-
pletely surrounded by myometrium circumferentially, with
no communication with the intrauterine cavity [69, 105].
Intramural EPs are notoriously challenging to diagnose on
ultrasound and have been mistaken for fibroids or intra-
uterine pregnancies [106].
Ovarian EPs may be suspected by ultrasound when
a hypoechogenic area is seen surrounded by a wide
Fig. 2 Tubal ectopic pregnancy by transvaginal ultrasound. The arrow
indicates the ectopic gestation with circumferential Doppler flow, called
the “Ring of Fire”
Fig. 3 Interstitial ectopic pregnancy by transvaginal ultrasound. The
arrow indicates thin (<5 mm) myometrium overlying the ectopic
pregnancy. This finding by ultrasound, in combination with the
lateral location of the gestation, has a reported specificity of 88-93 %
but a sensitivity of just 40 % [101].
Fig. 1 Tubal ectopic pregnancy by transvaginal ultrasound. The arrow
indicates the ectopic gestation with a surrounding hyperechoic ring,
called the ‘bagel’ or ‘tubal’ sign
Fig. 4 Interstitial ectopic pregnancy by magnetic resonance imaging,
T1 weighted. The arrow indicates thin (<5 mm) myometrium overlying
the ectopic pregnancy. In a stable patient, MRI may be useful in the
confirmation of interstitial pregnancy location
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echogenic ring with peripheral Doppler flow. Some may be
completely surrounded by ovarian cortex. [106, 107] A fetal
pole is seldom present [107]. When pressure is applied
with the transvaginal probe, an ovarian EP will move with
the ovary, and should be connected to the uterus by the
ovarian ligament [107, 108]. These EP can be difficult to
differentiate from ovarian cysts, which may have a similar
appearance and peripheral Doppler flow [108]. Given the
difficulty of making this diagnosis by imaging, laparoscopy
is often required for definitive diagnosis [107].
Abdominal EP is rare, and ultrasound guidelines are
few. Suggested guidelines include visualization of an extra-
uterine gestational sac, fetus and/or placenta, with no
myometrium seen between the fetus and urinary bladder
[109]. This gestational sac or fetus will be in unusually
close proximity to the anterior abdominal wall, and may
be surrounded by loops of bowel. There should be no
evidence of more common ectopic implantation sites,
such as the fallopian tubes or cesarean section scar [110].
Endometrial sampling
At many medical centers, a patient with a PUL and an
abnormal β-hCG trend as described above may receive
methotrexate (MTX) without precise diagnosis [111]. Up
to 40 % of these patients, however, may ultimately have
failing IUPs, unnecessarily exposing these patients to
MTX [112]. While not universally employed, endomet-
rial sampling may allow these patients to avoid unneces-
sary treatment with MTX [113].
Identification of villi on endometrial sampling is diagnos-
tic of a failed IUP, and in such cases, no further treatment
is usually needed [5, 114, 115]. Serum β-hCG should also
be checked the day after endometrial sampling; a decline
of 15–20 % after sampling indicates the disruption of a
Fig. 6 Cervical ectopic pregnancy by transvaginal ultrasound. Doppler
shows circumferential flow. The arrow indicates Doppler flow inside the
gestational sac, associated with the embryo. Such Doppler flow will not
be found in a spontaneous abortion, which may slide down into a
similar position at the cervix
Fig. 5 Interstitial ectopic pregnancy by transvaginal ultrasound. The
arrow indicates the ‘interstitial line,’ extending from the endometrium
to the cornua, abutting the suspicious mass
Fig. 7 Cesarean scar ectopic pregnancy by transvaginal ultrasound.
The arrow shows the gestational sac implanted in the region of the
cesarean scar, clearly outside the endometrial canal
Fig. 8 Cesarean scar ectopic pregnancy by transvaginal ultrasound.
The arrow indicates the thin myometrium (3 mm) between the bladder
(indicated with the number 1) and the gestational sac
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failing IUP, even if no villi are identified [5]. A postopera-
tive plateau or increase in the β-hCG value strongly sug-
gests an EP. A patient with an adequate decrease in the β-
hCG level after sampling can be monitored with serial β-
hCG measurements until levels are undetectable, or until
pathological evaluation of the curettage specimen shows
chorionic villi [116].
The standard endometrial sampling method for PUL
is D&C, though these are associated with greater cost
and anesthesia requirement than outpatient procedures
[112, 117, 118]. Endometrial biopsy pipelles, while
effective in screening for endometrial carcinoma, have
insufficient sensitivity and specificity to replace D&C in
the diagnosis of PUL [119, 120]. Karman cannulas, at-
tached to hand-held suction devices, are as efficacious
as D&C for diagnosing endometrial pathology and are
frequently used for the evacuation of first trimester
pregnancies in the outpatient setting [121–124]. In a re-
view of 45 patients with PUL and abnormal β-hCG
trends after IVF, over two-thirds of patients were diag-
nosed with failing IUP by final pathology and/or falling
β-hCG, and were spared MTX [116]. It is unknown
whether this device performs similarly in spontaneous
pregnancies.
Medical management
The most common interventions for the treatment of EP
are medical management with systemic MTX and surgical
removal of the pregnancy. Medical management of EP with
MTX has been demonstrated to be more cost-effective
than surgical management while maintaining similar treat-
ment success and future fertility [38, 125–127]. Injections
of hyperosmolar glucose into tubal EPs have been studied,
but have significantly higher failure rates than standard
medical or surgical management and are not recom-
mended [128–130].
MTX is a dihydrofolate reductase inhibitor, disrupting
DNA and RNA precursor synthesis; it targets rapidly
dividing cells and, in an EP, disrupts primarily tropho-
blastic tissue [131]. Its use as treatment for EP was first
reported in 1982 [132]. The most common side effects
associated with MTX treatment for EP include pelvic
pain, nausea, headaches, abdominal pain, and dermatitis.
Less common side effects include mucositis, diarrhea, and
alopecia [127, 133].
Several studies have demonstrated the efficacy of
intramuscular (IM) MTX for treatment of EP, though
success rates are inversely correlated to β-hCG levels
[134]. In a meta-analysis including 503 women with EPs
treated with single dose MTX, successful treatment,
defined as avoidance of surgery, for initial β-hCG levels
between 1000 and 1999 mIU/mL was 94.4 %, compared
with just 81.8 % in patients with starting β-hCG levels of
10,000 to 150,000 mIU/mL [134]. A β-hCG above 5000
mIU/mL was proposed as a relative contraindication to
treatment with MTX, with a success rate of just 85 %.
Pre-methotrexate assessment
Before treatment with MTX, blood work should be ob-
tained to assess hematologic, hepatic and renal function;
a chest x-ray should be considered in patients with active
pulmonary disease. The patient’s Rhesus (Rh) status must
also be obtained in order to determine the need for Rho(D)
immune globulin therapy, required in Rh negative patients.
A pelvic ultrasound should be obtained to characterize any
ectopic mass and exclude a concomitant IUP. Several con-
traindications for treatment of EP with MTX exist (Table 1)
[135]. Patients with ectopic pregnancies and relative con-
traindications to treatment with methotrexate may receive
the medication if deemed appropriate by the clinician;
these patients should be hemodynamically stable and well
counseled and have capacity to make the decision [6].
Patients should be advised to stop taking prenatal vita-
mins, as the folate supplementation will counteract the
action of MTX. Patients should also avoid excessive sun-
light due to possible MTX-induced dermatitis; nonsteroidal
Table 1 Absolute and relative contraindications of treatment of EP with MTX
Absolute Contraindications Relative Contraindications
Clinical instability or significant pain suggestive of ruptured EP Presence of fetal cardiac activity
Heterotopic pregnancy with viable and desired IUP β-hCG level over 5000 mIU/mL
Liver function tests more than 2 times the upper limit of normal An ectopic mass size greater than 4 cm in largest dimension
White blood cell count of <1500/uL Patient refusal of blood transfusion




Active peptic ulcer disease
Moderate to severe anemia
Sensitivity to methotrexate
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anti-inflammatory drugs, which may delay renal excretion
of MTX; alcohol, which may lead to elevation of hepatic
enzymes; and sexual activity, vigorous physical activity and
pelvic exams, which could lead to rupture of the EP [136].
Systemic methotrexate
Single dose methotrexate The single dose regimen
consists of an IM injection of MTX (50 mg/m2 of body
surface area), with administration of additional doses at
weekly intervals in patients with an inadequate response
(Table 2) [6]. Repeat injections are permitted every 7 days
for up to 4 doses; a second dose is needed in 20 % or
more of patients, while less than 1 % of patients require
3 or more doses [137]. The single dose regimen is asso-
ciated with fewer side effects as compared to other regi-
mens [6, 138, 139].
Two dose methotrexate
A two dose regimen has been proposed by Barnhart and
colleagues (Table 3) [133]. In their prospective study of 101
women with a mean serum β-hCG at treatment initiation
of 2013 mIU/mL, the success rate, defined as avoidance of
surgery, was 87 %. Patients suffered just mild and transient
side effects, including nausea, headaches and abdominal
pain, despite the lack of leucovorin supplementation.
Multiple dose methotrexate
The multiple dose regimen was derived from chemo-
therapeutic regimens for gestational trophoblastic dis-
ease, involving administration of MTX and leucovorin
(folinic acid) on alternating days for 8 days or until the
β-hCG falls by 15 % from its peak value (Table 4) [6].
Up to 50 % of patients will not require the full 8 day
regimen [6]. Leucovorin is administered to counteract
the mechanism of MTX to limit side effects.
The reported success rates among the dosing regimens
vary in the literature [127, 137, 138]. A recent randomized
controlled trial of 120 women receiving single or multiple
dose MTX reported no difference in success rates, though
the time until β-hCG normalization was longer following
the single dose regimen (22.3 vs. 18.3 days, respectively)
[140]. Conversely, a meta-analysis of 1327 EPs reported
that the rate of successful treatment with multiple dose
MTX was significantly higher than with single dose MTX
(92.7 vs. 88.1 %, respectively) [137]. Side effects, including
nausea, vomiting and alopecia, were less common in the
single dose treatment group. Of note, both treatment regi-
mens were more likely to be successful in patients report-
ing side effects of the MTX.
Few comparisons have been published involving the two
dose regimen. A retrospective comparison of 87 women
receiving either single or two dose MTX regimens reported
comparable success rates of 87 and 90 % at mean starting
serum hCGs of 4801 and 4278 mIU/mL, respectively, and
no difference in side effects [141]. In the literature, it is
unclear which of these (single, two or multiple dose) regi-
mens is used most commonly, though single and multiple
dose regimens are discussed more often than the two dose
regimen; MTX dosing is likely dependent on the provider
and/or institution.
Regardless of which treatment regimen is chosen, if
the β-hCG level does not decline adequately—after the
multiple dose regimen, or 4 doses of MTX in single or
two dose regimens—surgical management should be
considered. A continued rise in serum β-hCG through-
out the multiple dose regimen or after 2 doses of single
dose MTX may indicate higher risk of rupture of a tubal
EP [6, 142]. Finally, medical management should be
abandoned in favor of surgical management if the
patient presents with hemodynamic instability or other
clinical parameters concerning for ruptured EP, such as
pain. If a patient’s serum β-hCG declines adequately
and she requires no further intervention, the β-hCG
level should be monitored weekly to an undetectable
level. On average, the β-hCG normalizes in 2 to 3 weeks,
but can take up to 8 weeks in patients with higher start-
ing β-hCG levels [6, 143].
Surgical management
Surgical management is indicated in patients with con-
traindications to medical treatment as described in the
previous section, hemodynamic compromise or other
clinical signs of ruptured EP including pain or evidence
of intra-abdominal bleeding, and according to patient
preference.
The standard surgical intervention was laparotomy until
the laparoscopic approach was introduced in 1973 by Sha-
piro and Adler; it has since gained wide acceptance [144].
Table 2 Single dose methotrexate (MTX) for treatment of ectopic pregnancy
Day 1 Day 4 Day 7
Labs 1. β-hCG β-hCG 1. β-hCG
2. Safety labs (complete blood count, BUN, creatinine, AST, ALT) 2. Safety labs
3. Blood type and antibody screen
Action Give MTX (50 mg/m2 of body surface area IM) no action β-hCG decline <15 % from Day 4 to Day 7: MTX, return to day 1 of
protocol. Repeat MTX up to a total of 4 doses
β-hCG decline >15 %: Check β-hCG at 1 week intervals until zero.
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Three prospective randomized trials have demonstrated
the superiority of a laparoscopic approach over laparot-
omy in terms of lower blood loss, pain medication re-
quirement, length of hospital stay and cost [145–148].
Reproductive outcomes, including rates of recurrent EP
and subsequent IUP, are not significantly different be-
tween laparoscopy and laparotomy [149].
Regardless of the mode of abdominal entry, two methods
of excision of a tubal EP have been extensively reported:
Salpingectomy, or removal of the fallopian tube in part or
in full, and salpingostomy (also called salpingotomy), or
removal of the EP through a tubal incision while leaving
the tube in situ. Salpingectomy is recommended in cases
of extensive tubal damage and/or rupture, uncontrolled
bleeding, prior tubal sterilization, or a large tubal EP (5 cm
or more in diameter) [143]. The surgical approach is also
determined by the status of the patient’s contralateral fallo-
pian tube, the patient’s plans for future fertility, and sur-
geon comfort or preference.
Salpingectomy
Despite being termed “radical” in the literature, salpingec-
tomy results in similar rates of subsequent IUP and ectopic
recurrence as compared to salpingostomy. A randomized
control trial of 446 women undergoing salpingostomy or
salpingectomy reported similar recurrent EP and ongoing
pregnancy rates between groups: 8 and 60.7 %, respectively,
after salpingostomy and 5 and 56.2 %, respectively, after
salpingectomy [39]. Persistent trophoblastic tissue, which
usually requires treatment with MTX, was more common
after salpingostomy (7 %) than after salpingectomy (<1 %).
Of note, 43 women (20 %) randomized to salpingostomy
underwent an intra-operative conversion to salpingectomy
during the initial surgery due to uncontrolled bleeding.
Similarly, in a review of 1064 women with EPs attempting
subsequent conception, the rates of intrauterine pregnan-
cies within 2 years were not significantly different, at 67 %
after salpingectomy and 76 % after salpingostomy [38]. The
rate of EP recurrence was also similar between groups, or
18.5 % overall. Following salpingectomy, if final pathologic
analysis of the fallopian tube demonstrates evidence of a
tubal gestation, no follow up β-hCG levels or any other as-
sessment is needed.
Salpingostomy
Intraoperatively, if salpingostomy is planned, dilute vaso-
pressin can be injected at the planned incision site for
additional hemostasis [143]. After a 1–2 cm linear
Table 4 Multiple dose methotrexate (MTX) and leucovorin (LEU) for treatment of ectopic pregnancy






Labs 1. β-hCG β-hCG β-hCG β-hCG
2. Safety labs (complete
blood count, BUN,
creatinine, AST, ALT)
3. Blood type and
antibody screen
Action MTX (1 mg/kg, IM) LEU (0.1 mg/kg, IM) β-hCG decline <15 %
from Day 1 to Day 3:
Give MTX
LEU β-hCG decline <15 %
from Day 3 to Day 5:
Give MTX
LEU β-hCG decline <15 %
from Day 5 to Day 7:
Give MTX
LEU
β-hCG decline >15 %
from Day 1 to Day 3:
Check β-hCG at one
week intervals until zero.
β-hCG decline >15 %
from Day 3 to Day 5:
Check β-hCG at one
week intervals until zero.
β-hCG decline >15 %




Table 3 Two dose methotrexate (MTX) for treatment of ectopic pregnancy
Day 0 Day 4 Day 7 Day 11 Day 14
Labs 1. β-hCG β-hCG 1. β-hCG β-hCG 1. β-hCG
2. Safety labs (complete blood
count, BUN, creatinine, AST, ALT)
2. Safety labs 2. Safety labs
3. Blood type and antibody screen
Action Give MTX (50 mg/m2 of body
surface area IM)
Give MTX (50 mg/m2
of body surface area IM)
β-hCG decline <15 %
from Day 4 to Day 7:
Give MTX
β-hCG decline <15 %
from Day 7 to Day 11:
Give MTX
β-hCG decline <15 %
from Day 11 to Day 14:
Refer for surgery
β-hCG decline >15 %
from Day 4 to Day 7:
Check β-hCG at 1 week
intervals until zero.
β-hCG decline >15 %
from Day 7 to Day 11:
Check β-hCG at 1 week
intervals until zero.
β-hCG decline >15 %
from Day 11 to Day 14:
Check β-hCG at 1 week
intervals until zero.
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incision is made with electrocautery, laser or scissors
over the bulging ectopic gestation, the contents are re-
moved using forceps or high pressure irrigation, also
called hydrodissection [143, 150–152]. The use of hydro-
dissection to flush out gestational products may be pref-
erable to piecemeal removal with forceps, as the latter
can lead to incomplete removal of trophoblastic tissue
[4]. The tubal incision can be left open to heal by sec-
ondary intention or sutured closed; a Cochrane review
reported an insignificant difference in rates of recurrent
EP and subsequent IUP between the two techniques
[148].
After salpingostomy, weekly β-hCG measurements are
necessary to rule out persistent trophoblastic tissue,
which can occur in up to 20 % of cases [153]. Adminis-
tration of a single dose of intratubal MTX intraopera-
tively or IM MTX within 24 h postoperatively has been
shown to decrease the rate of persistent trophoblastic
tissue (from 14.5–17.5 to 0–1.9 %) [154, 155].
Expectant management
A carefully selected subset of patients may be candidates
for expectant management of tubal EP. Studies suggest
that well-counseled, stable women with EPs and serum
β-hCG of 175–200 mIU/mL and declining may be can-
didates for expectant management.
In an observational study of 107 patients diagnosed
with tubal EP by transvaginal ultrasound (a mass separ-
ate from the ovary), expectant management was offered
to asymptomatic patients without fetal cardiac activity
[156]. Expectant management was discontinued due to
severe pain or failure of the serum β-hCG to decline on
sequential measurements. Ninety-six percent of women
with a β-hCG of 175 mIU/mL or less did not require
other treatment, compared to 66 % of those with β-hCG
of 175–1500 mIU/mL and just 21 % of those with β-
hCG above 1500 mIU/mL. Expectant management was
more likely to be successful in patients with serum pro-
gesterone below 10 nmol/L (3.1 ng/mL), gestational age
less than 6 weeks, and EP mass greater than 15 mm.
Similarly, a prospective observational study of 118 pa-
tients with EPs managed expectantly reported that 88 %
resolved with β-hCG levels below 200 mIU/mL, as
opposed to just 25 % with β-hCG levels above 2000
mIU/mL [157].
The American College of Obstetricians and Gyne-
cologists recommends that patients with EPs and
serum β-hCG less than 200 mIU/mL and decreasing
(though this is not strictly defined) are potential can-
didates for expectant management [136]. Patients
undergoing expectant management for EP must be
reliable for follow up, and willing and able to accept
the risks of EP rupture, hemorrhage and emergency
surgery.
Management of nontubal EP
Ovarian EP
Management of ovarian EP is most commonly surgical,
and little data is available on the medical management
of this condition [6]. Successful treatment of ovarian EPs
with systemic MTX alone has been described, using
either the single or multiple dose regimens, up to a
serum β-hCG of 5201 mIU/mL [158, 159]. Systemic
MTX has also been described, following limited biopsy
of a suspected ovarian EP, to address residual tropho-
blastic tissue [160, 161]. Successful management with
transvaginal or laparoscopic injections of 50 mg of MTX
directly into the ovarian EP, with β-hCG levels up to
12,075 mIU/mL, has also been reported [162, 163].
Often, laparoscopy is required for diagnosis, at which
point definitive surgical management is often completed
[107]. Management of ovarian EPs is primary surgical, and
laparoscopic surgery has become the standard for manage-
ment of hemodynamically stable patients with ovarian EPs
[164, 165]. Resection of the EP and retention of the ovary
is a reasonable surgical objective, particularly in patients
desiring future fertility. This resection has most commonly
taken the form of an ovarian wedge resection, attempting
to remove as little normal ovarian tissue as possible [165].
In reports of surgical management of ovarian ectopic,
hemostasis is obtained with electrocautery or ultrasonic
energy; the latter is less damaging to the surrounding ovar-
ian cortex [166, 167].
Cervical EP
Management of cervical pregnancies may be medical or
surgical, with many centers utilizing a combination of
approaches. The use of single or multiple dose systemic
MTX and/or local MTX has been described in case
reports and small series [168–170]. A series of 38 cer-
vical EPs treated with local MTX, with additional local
potassium chloride (KCl) in the presence of fetal cardiac
activity, reported an overall success rate of 87 %; all fail-
ures had fetal cardiac activity [171]. In a review of 52
cervical EPs, 61.5 % were successfully treated with
upfront systemic or local MTX [172]. Gestational age
greater than 9 weeks, β-hCG titer over 10,000 mIU/mL,
presence of fetal cardiac activity or fetal crown-rump
length greater than 10 mm were associated with failure
of upfront MTX.
Dilation and curettage is seldom used in isolation as a
first line treatment, given the risk of hemorrhage; in a
review of 15 cases with mean gestational age of 8.9 weeks,
the risk of hysterectomy was 40 % [103]. Methods for de-
creasing the risk of bleeding include injection of vasocon-
stricting agents into the cervix, such as dilute vasopressin,
or placement of cervical stay sutures [173]. Placement of
intracervical catheter for tamponade, such as a 30 mL foley
catheter, has also been described [174]. In the presence of
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fetal cardiac activity, preoperative injection of feticides may
decrease the risk of hemorrhage [175].
Uterine artery embolization (UAE) may have a role in
preventing or controlling hemorrhage; case series have
reported both prophylactic UAE prior to medical and/or
surgical management, or emergent use to control
hemorrhage [170, 176–178]. This therapy is not currently
recommended for women who wish to conceive in the
future, as its ramifications for fertility have not been
conclusively described.
Cesarean scar EP
Interruption of a cesarean scar EP upon diagnosis is rec-
ommended, given the risk of hemorrhage, hysterectomy
and maternal morbidity [179, 180]. Live births resulting
from a cesarean scar ectopic implantation have been
described; however, these deliveries are frequently
associated with hemorrhage and emergent cesarean
hysterectomy [9, 181, 182]. In a series of 10 patients
with cesarean scar EPs with fetal cardiac activity who
elected for expectant management, 4 patients (40 %)
had live births, 3 of whom (75 %) required hysterecto-
mies; overall, 80 % required hysterectomies [183].
Medical management with single or multiple dose
systemic MTX regimens has been described. Patients with
serum β-hCG greater than 6000 mIU/mL may be at higher
risk of requiring additional therapies, including local MTX,
D&C or uterine artery embolization (UAE) [9, 64]. Local
injections of MTX or KCl have also been described, usually
in conjunction with systemic MTX or other surgical man-
agement (D&C or hysteroscopy) [184].
Several surgical approaches have also been reported,
with the benefit of leading to more rapid resolution of
β-hCG levels as compared to medical management [185].
Regardless of the chosen treatment modality, serum β-
hCG should be followed to zero, as persistent tropho-
blastic tissue may occur after any medical or surgical
treatments except hysterectomy [9, 186]. In patients
undergoing upfront surgical management, D&C alone is
often complicated by hemorrhage. In a meta-analysis of 21
cases, 76 % required further treatment, and 14 % required
hysterectomy [64]. Initial steps for managing hemorrhage
include tamponade with a transcervical catheter and
hemostatic cervical cerclage sutures [187]. UAE has been
used as both hemorrhage prophylaxis and salvage therapy
in the event of hemorrhage [188]. UAE is not currently
recommended for patients desiring future fertility.
Hysteroscopic resection of cesarean scar EPs has been
performed successfully and without complication using
biopolar or ‘electric’ loops, in patients with serum β-hCG
up to 28,333 mIU/mL [186, 189, 190]. Hysteroscopic re-
section is not recommended when the residual myome-
trium is less than 3 mm, given the risk of anterior wall
perforation and bladder injury [191, 192].
Transabdominal excision of these lesions has been de-
scribed by laparotomy, and standard or robotic-assisted
laparoscopy [191]. Resection also allows for revision of
the lower uterine segment, which theoretically may re-
duce risk for recurrence [193]. Laparotomy may be indi-
cated in patients with suspected uterine rupture and
hemodynamic instability, and hysterectomy may be re-
quired for otherwise uncontrollable hemorrhage [194].
Definitive management with total laparoscopic hyster-
ectomy has also been described, in a patient with a
starting β-hCG of 155,009 mIU/mL who failed treat-
ment with local KCl and multiple dose MTX [195]. Of
note, complications of medical or surgical management
include formation of arterio-venous malformations,
which are prone to bleeding; in one series of 60 cesarean
scar EPs, this occurred at a rate of 8.5 %, requiring UAE
or hysterectomy (Fig. 9) [183].
Interstitial EP
In patients who are hemodynamically stable without
evidence of rupture of the interstitial EP, non-surgical
management may be appropriate. Both single dose and
Fig. 9 Left uterine artery arterio-venous malformation (AVM) by pelvic
angiogram. This patient had undergone an uncomplicated
ultrasound-guided D&C for a 10 week size cesarean scar ectopic
pregnancy 2 months prior to presentation with vaginal bleeding and
diagnosis of a left uterine artery AVM (arrow). The AVM was embolized
with coils, but the patient required emergent hysterectomy for
hemorrhage
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multiple dose MTX regimens have been used to treat
interstitial EPs with comparable success, ranging from
66 to 100 % [196]. UAE has also been successfully used
as an adjunct to these therapies [197, 198]. Local MTX
has also been used; a meta-analysis of 11 cases reported
a success rate of 86 %, up to a serum hCG of 35,000
mIU/mL [4].
Surgical intervention is indicated following failed
medical management, according to patient preference,
or when the patient demonstrates hemodynamic in-
stability and/or findings concerning for rupture of an
interstitial EP, including pain or evidence of hemoperi-
toneum on imaging. Laparotomy and hysterectomy
were formerly first line treatment, likely due to late
diagnosis of interstitial pregnancies and higher rates of
rupture and hemorrhage. These methods may still be
necessary in patients with hemodynamic instability and
severe hemorrhage.
Minimally invasive surgeries are increasingly pursued as
imaging modalities allow for earlier diagnosis. Small case
series have described ultrasound or laparoscopy-guided
dilation and curettage [199–201]. Several laparoscopic sur-
gical approaches have been described, including cornuost-
omy, salpingostomy, and cornual resection.
Cornuostomy entails injection of dilute vasopressin at
the cornua followed by a linear incision, through which
the gestation is removed with blunt and/or sharp dissec-
tion or hydrodissection, after which the incision is closed
with absorbable suture [4]. Case series have also de-
scribed successful surgical management with placement
of an Endoloop around the base of the cornua before or
after excision for both hemostasis and closure [202].
Less commonly, salpingostomy for interstitial ectopic
has been reported, which is most appropriate for inter-
stitial EP less than 3.5 cm, given the smaller incision
with limited visualization [203, 204].
Cornual resection has been recommended for surgical
management of more advanced interstitial pregnancies
(greater than 3–4 cm) [12, 205]. This technique entails
injection of dilute vasopressin followed by a circumfer-
ential incision using scissors or an energy source—elec-
trosurgical or ultrasonic—preferably 1–2 cm above the
cornual pregnancy to allow for redundant serosa and
myometrium for closure [11, 12]. This incision should
be closed in layers akin to a myomectomy closure. The
fallopian tube adjacent to this cornua should also be ex-
cised. UAE has also been used as a prophylactic measure
before laparoscopic cornual resection [206].
Intramural EP
As with other types and locations of EP, management of
intramural EPs is largely dictated by patients’ clinical sta-
bility at presentation. In clinically stable patients with
intramural EPs diagnosed by imaging, medical manage-
ment is an option. In case reports, intramural EPs have
been treated with single or multiple dose systemic MTX,
successful in patients with serum β-hCG up to 25,140
mIU/ml [207–209]. Successful management with local
MTX and KCl for an intramural EP with fetal cardiac
activity and a β-hCG of 74,872 mIU/mL has also been re-
ported, as well as UAE for an intramural EP with a β-hCG
of 12,250 mIU/mL [210, 211].
Most cases of intramural EP reported in the literature
have been managed surgically via laparotomy, sometimes
requiring hysterectomy, as many patients present with
rupture of the EP and hemorrhage [13]. Given the increas-
ing ability of noninvasive imaging to diagnose intramural
EPs and the advancement of minimally invasive surgery,
more recent case reports have described laparoscopic ex-
cision of intramural ectopic gestations [212, 213]. A surgi-
cal approach should be determined by a patient’s clinical
stability, desire for future fertility, and location of the ec-
topic gestation.
Abdominal EP
Intervention for resolution of an abdominal EP is
recommended upon diagnosis, given the extremely high
risk for maternal morbidity; the mortality risk associ-
ated with abdominal EPs is nearly 8 times the rate with
tubal EPs [16]. Rare reports detail expectant manage-
ment in order to attain a live birth. Expectant manage-
ment of abdominal EPs may potentially be considered
when the diagnosis is made after 20 weeks of gestation
in a healthy patient who can be followed very closely
through a tertiary care center. The fetus should have no
congenital malformations, and the placenta should be
implanted away from the upper abdomen. Delivery is
recommended at 34 weeks, and the placenta is often left
in place given the risk for hemorrhage [214, 215].
Most abdominal EPs reported in the literature have
been managed surgically; the operative approach must be
tailored to the patient’s clinical presentation and stability,
and the location of the EP. Abdominal EPs have been
approached by laparoscopy or laparotomy, with or with-
out prophylactic embolization of the placental bed; more
recent cases in the literature have been managed laparo-
scopically in hemodynamically stable patients [216–218].
Intraoperative blood transfusion is common; in a meta-
analysis, the highest transfusion rate was associated with
hepatic (46 %) and retroperitoneal (40 %) implantations,
while abdominal wall implantations had the lowest trans-
fusion rate (14 %) [16].
When abdominal EPs are removed surgically at any
gestational age—though more commonly after 20 weeks
of gestation—the placenta can be left in place to avoid
hemorrhage [16]. Embolization of the remaining placenta
and/or administration of systemic MTX or mifepristone
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have been employed to hasten resolution of these retained
placentas [219, 220]. The most common complication of
an intraabdominal retained placenta is infection [16].
As diagnostic modalities have advanced and these
pregnancies are diagnosed earlier, case reports of med-
ical management for abdominal EP have been pub-
lished. Medical management with systemic MTX and/
or local injections of MTX or KCl has been reported,
though nearly half may require subsequent surgical
management [16, 221–223]. Despite logistic regression,
a meta-analysis failed to identify risk factors for failed
medical management [16].
Heterotopic pregnancies
Treatment of a HP is tailored to the specific EP location,
and the patient’s clinical presentation and stability [78].
Medical management of tubal HPs includes local injections
of KCl or a hyperosmolar glucose solution, though over
half of tubal HPs managed with local KCl may require sub-
sequent salpingectomy [17, 224]. Treatment with systemic
or local MTX, a known teratogen, is contraindicated in the
presence of a viable IUP [225]. Surgical management has
been described more frequently, as patients with tubal HPs
present more often with rupture and hemodynamic com-
promise than those with tubal EPs [226]. Salpingectomy is
preferable to salpingostomy as persistent trophoblastic
tissue cannot be monitored in the setting of ongoing IUP
[78]. Patients with HPs suffer spontaneous abortions at
higher rates than intrauterine-only pregnancies (up to
30 %) [18].
Nontubal HP
For the management of interstitial HPs, expectant man-
agement, aspiration or injection of hyperosmolar glucose
of the interstitial HP, and cornual resections have been
reported, leading to live birth [227–229]. One patient
attempting expectant management required a laparot-
omy for rupture of the interstitial EP [227].
Cesarean HPs have been successfully managed using
local KCl and/or aspiration of the gestation, or excision
by laparoscopy or hysteroscopy [230]. Hysteroscopy car-
ries the theoretical risk of disrupting an IUP due to the
high pressure infusion of fluid.
Cervical HPs addressed with expectant management,
local KCl or hyperosmolar glucose injections, extraction
with forceps, suction curettage or hysteroscopic resec-
tion, with or without subsequent foley tamponade, have
resulted in live birth. Rare case reports also detail cerc-
lage placement following intervention. Following this
range of interventions, a review of 30 cases reported a
live birth rate of 80 % [231].
Abdominal HPs are rarely encountered, though live
birth after local injection of KCl into the abdominal
pregnancy has been reported in 3 cases [232]. Ovarian
HPs are similarly rare; live birth after local hyperosmolar
glucose injection has been reported, as well as after lap-
aroscopic wedge resection; surgical intervention carries
the theoretical risk of interrupting hormonal support of
the coexisting IUP by the corpus luteum [233, 234].
Recurrence and future fertility
The risk of recurrence of tubal EP ranges from 5 to 25 %
[38–40, 235]. The risk of recurrent EP is not affected by
treatment modality—medical or surgical—or surgical pro-
cedure [38]. In a randomized controlled study of 446
women undergoing surgical management for tubal EP, the
recurrence rate was similar after salpingostomy (8 %) and
salpingectomy (5 %) [39].
A review of 53 cases of prior interstitial EP reported a re-
currence rate of 9.4 % following either medical or surgical
management [236]. In patients with a prior interstitial EP,
data is limited regarding the risk of uterine rupture in a
subsequent IUP, though uterine rupture has been reported
after both expectant management and cornual resection
[237, 238]. Vaginal deliveries have been reported following
cornuostomy or cornual resection; the optimal mode of
delivery in this group remains to be determined [12].
The reported rate of recurrent cesarean scar EP is highly
variable, as high as 25 % in small series [239, 240]. Risk
factors for recurrence are bulging of the prior cesarean
scar EP into the uterovesical fold, initial presentation with
irregular vaginal bleeding or pain, early termination
(≤56 days) of the first cesarean scar EP, prior cesarean de-
livery at a rural community hospital and thin lower uterine
segment (5 mm or less at the time of diagnosis of recur-
rent cesarean scar EP) [241].
The risk of recurrent cervical EP appears to be low:
One recurrence was noted in a series of 34 pregnant
women with prior cervical EP treated with several differ-
ent modalities [67]. The data are insufficient to com-
ment on subsequent IUP and recurrence rates in
patients with prior ovarian, intramural or abdominal
EPs. Rates of recurrence and IUP after HP have not been
extensively reported in the literature, and likely depend
on the location of the HP and the treatment modality.
Regardless of ectopic location, conception is not recom-
mended for 3 months after exposure to MTX, though data
for this recommendation is lacking [6]. Results of
population-based studies of pregnancy outcomes after a
prior tubal EP are encouraging, and independent of treat-
ment modality. The rates of IUP have been shown to be
similar following salpingectomy and salpingostomy in sev-
eral large series [39, 40]. Additionally, among 1064 women
with prior tubal EPs attempting conception, the rates of
IUP within 2 years were similar among salpingectomy
(67 %), salpingostomy (76 %), and medical management
(76 %) [38]. After two prior EPs, however, the rate of
subsequent IUP may be as low as 4 % [235].
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Conclusions
Ectopic pregnancy is a relatively common clinical scenario
in general gynecology and reproductive medicine. While
tubal pregnancies are the most common, EPs can occur
throughout the abdomen and pelvis. Treatment in stable
patients is often medical, though patients meeting certain
clinical criteria or with EPs outside the fallopian tube may
require differing and/or more invasive treatment, includ-
ing excision by laparoscopy or, less commonly, laparot-
omy. Of patients with tubal EPs, the likelihood of future
IUP is high and independent of treatment modality.
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